Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination among outpatients receiving immunosuppressive therapy: A monocentric observational study in Japan

Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination among outpatients receiving immunosuppressive therapy: A monocentric observational study in Japan - Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination among outpatients receiving immunosuppressive therapy: A monocentric observational study in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044499

Enrollment

200

Registered

2021-06-11

Start date

2021-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who were receiving immunosuppressive therapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were receiving immunosuppressive therapy, systemic steroids, immunosuppressive drugs, immunomodulators, anti-rheumatic drugs, biologics, and JAK inhibitors, for interstitial pneumonia and autoimmune diseases while attending the outpatient clinic of the Department of Respiratory Medicine, Rheumatology, Hepatobiliary and Pancreatic Diseases, and Dermatology at our hospital during the above registration period.

Exclusion criteria

Exclusion criteria: age less than 15 years, infected with SARS-CoV-2 and quarantined, already vaccinated, not willing to be vaccinated on their own or on the recommendation of their physician, undergoing treatment for cancer, and not providing informed consent.

Design outcomes

Primary

Measure	Time frame
Antibody titer of anti-spike protein IgG before first vaccination, 3 weeks, 5 weeks, 90 days, and 180 days after vaccination	—

Countries

Japan

Contacts

Public ContactMakoto Hibino

Shonan Fujisawa Tokushukai Hospital Respiratory Medicine

chigasaki30@gamil.com0466351177

Outcome results